EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes

Alfredo Ramírez-Reveco iD, Gerardo Velásquez, Christopher Aros, Gabriela Navarrete, Franz Villarroel-Espíndola, Maritza Navarrete, Alberto Fica, Anita Plaza, Natalia Castro, Claudio Verdugo, Gerardo Acosta-Jamett iD, Cristóbal C Verdugo iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0270388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Alfredo Ramírez-Reveco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Ciencia Animal, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main objective of this study was to estimate the performance, under local epidemiological conditions, of two in-house ELISA assays for the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulins. A total of 94 serum samples were used for the assessment, where 44 corresponded to sera collected before the pandemic (free of SARS-CoV-2 antibodies), and 50 sera were collected from confirmed COVID-19 patients admitted to the main public hospital in the city of Valdivia, southern Chile. The Nucleocapsid (Np) and the receptor-binding domain (RBD) proteins were separately used as antigens (Np and RBD ELISA, respectively) to assess their diagnostic performance. A receiver operating characteristic (ROC) analysis was performed to estimate the optical density (OD) cut-off that maximized the sensitivity (Se) and specificity (Sp) of the ELISA assays. Np ELISA had a mean Se of 94% (95% CI = 83.5–98.8%) and a mean Sp of 100% (95% CI = 92.0–100%), with an OD 450 nm positive cut-off value of 0.88. On the other hand, RBD ELISA presented a mean Se of 96% (95% CI = 86.3–99.5%) and a mean Sp of 90% (95% CI = 78.3–97.5%), with an OD 450 nm positive cut off value of 0.996. Non-significant differences were observed between the Se distributions of Np and RBD ELISAs, but the latter presented a significant lower Sp than Np ELISA. In parallel, collected sera were also analyzed using a commercial lateral flow chromatographic immunoassay (LFCI), to compare the performance of the in-house ELISA assays against a commercial test. The LFCI had a mean sensitivity of 94% (95% CI = 87.4–100%) and a mean specificity of 100% (95% CI = 100–100%). When compared to Np ELISA, non-significant differences were observed on the performance distributions. Conversely, RBD ELISA had a significant lower Sp than the LFCI. Although, Np ELISA presented a similar performance to the commercial test, this was 2.5 times cheaper than the LFCI assay (labor cost not considered). Thus, the in-house Np ELISA could be a suitable alternative tool, in resource limited environments, for the surveillance of SARS-CoV-2 infection, supporting further epidemiological studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Immunoglobulin AEnzyme-Linked Immunosorbent AssayImmunoglobulin GSensitivity and SpecificityImmunoglobulin MAntibodies, Viral

Substanzen

Immunoglobulin AImmunoglobulin GImmunoglobulin MAntibodies, Viral

Autor:innen und Institutionen

  • Instituto de Ciencia Animal, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile.
  • Laboratorio de Biología Molecular, Hospital Base de Valdivia (HBV), Valdivia, Chile.
  • Escuela de Bioquímica, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile.
  • Laboratorio Medicina Traslacional, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.
  • Sub Departamento de Medicina, Hospital Base Valdivia; Instituto Medicina, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile.
  • Center for the Surveillance and Evolution of Infectious Diseases (CSEID), Universidad Austral de Chile, Valdivia, Chile.

ORCID-Profile: Alfredo Ramírez-Reveco, Gerardo Acosta-Jamett, Cristóbal C Verdugo

Förderung

  • Agencia Nacional de Investigación y Desarrollo

Zitieren

APA

Ramírez-Reveco, A., Velásquez, G., Aros, C., Navarrete, G., Villarroel-Espíndola, F., Navarrete, M., Fica, A., Plaza, A., Castro, N., Verdugo, C., Acosta-Jamett, G., & Verdugo, C. C. (2023). Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes. PLOS ONE. https://doi.org/10.1371/journal.pone.0270388

Vancouver

Ramírez-Reveco A, Velásquez G, Aros C, Navarrete G, Villarroel-Espíndola F, Navarrete M, et al. Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes. PLOS ONE. 2023. doi:10.1371/journal.pone.0270388

BibTeX
@article{RamrezReveco2023,
  author = {Ramírez-Reveco, Alfredo and Velásquez, Gerardo and Aros, Christopher and Navarrete, Gabriela and Villarroel-Espíndola, Franz and Navarrete, Maritza and Fica, Alberto and Plaza, Anita and Castro, Natalia and Verdugo, Claudio and Acosta-Jamett, Gerardo and Verdugo, Cristóbal C},
  title = {Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0270388}
}
Kostenlos starten →